{"nctId":"NCT00659269","briefTitle":"A Randomized Phase III Study of Vitamins B6 and B12 to Prevent Chemotherapy-Induced Neuropathy in Cancer Patients","startDateStruct":{"date":"2006-07"},"conditions":["Cancer"],"count":319,"armGroups":[{"label":"Multivitamin (MV)","type":"ACTIVE_COMPARATOR","interventionNames":["Dietary Supplement: Multivitamin (MV)","Drug: Chemotherapy"]},{"label":"Multivitamin + Vitamin B12 + Vitamin B6","type":"EXPERIMENTAL","interventionNames":["Dietary Supplement: Multivitamin + Vitamin B12 + Vitamin B6","Drug: Chemotherapy"]}],"interventions":[{"name":"Multivitamin (MV)","otherNames":[]},{"name":"Multivitamin + Vitamin B12 + Vitamin B6","otherNames":[]},{"name":"Chemotherapy","otherNames":["Cisplatin (Platinol, Platinol-AQ)","Oxaliplatin (Eloxatin)","Paclitaxel (Taxol, Abraxane)","Docetaxel (Taxotere)","Vincristine (Oncovin)","Vinorelbine tartrate (Navelbine)"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. All patients, 18 years of age or older, with a cancer treated with any of the following drugs are eligible:\n\n   * Taxanes, vinca alkaloid analogs, heavy metals.\n   * Each patient will be allocated to the following 3 groups:\n\n     * Group 1 (Heavy metals): Patients treated with cisplatin (\\>25 mg/m2/week dose intensity) or oxaliplatin\n     * Group 2 (Taxane): Patients treated with paclitaxel, docetaxel or abraxane\n     * Group 3 (Vinca alkaloids): Patients treated with vincristine and vinorelbine.\n2. Patients must have a life expectancy of at least 24 weeks.\n3. Patients must have a Zubrod performance status of 0-2.\n4. Patients must sign an informed consent.\n5. Patients may have a grade 0 (chemotherapy naive) or 1 neuropathy (history of prior chemotherapy) prior to entry.\n\nExclusion Criteria:\n\n1. Patients with symptomatic brain metastases are excluded from this study.\n2. Pregnant women or nursing mothers are not eligible for this trial. Patients of child bearing potential must use adequate contraception.\n3. Patients may receive no other concurrent complementary medicines during this study.\n4. Patients with neuropathy induced diabetes are not eligible for this study\n5. Patients with severe medical problems such as uncontrolled diabetes mellitus or cardiovascular disease or active infections are not eligible for this trial.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Neurotoxicity Assessment at Baseline","description":"Neurotoxicity is evaluated using The Functional Assessment of Cancer Therapy-Taxane (FACT-Tax) questionnaire. FACT-Tax is a validated, self-reported instrument. The questionnaire consists of 11 questions and possible scores for each question range from 0 (no neurotoxicity symptoms) to 4 (worst possible neurotoxicity symptoms). The total score for any patient can therefore range from 0 to 44. The questionnaire is given to patients to fill out at baseline (prior to chemotherapy treatment) and the mean total score for all patients is reported.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.5","spread":"8.5"},{"groupId":"OG001","value":"7.3","spread":"7.3"},{"groupId":"OG002","value":"5.23","spread":"5.86"},{"groupId":"OG003","value":"4.58","spread":"5.34"},{"groupId":"OG004","value":"6.80","spread":"5.09"},{"groupId":"OG005","value":"2.08","spread":"2.02"}]}]}]},{"type":"PRIMARY","title":"Neurotoxicity Assessment at Cycle 2","description":"Neurotoxicity is evaluated using The Functional Assessment of Cancer Therapy-Taxane (FACT-Tax) questionnaire. FACT-Tax is a validated, self-reported instrument. The questionnaire consists of 11 questions and possible scores for each question range from 0 (no neurotoxicity symptoms) to 4 (worst possible neurotoxicity symptoms). The total score for any patient can therefore range from 0 to 44. The questionnaire is given to patients to complete at completion of cycle 2 of chemotherapy treatment and the mean total score for all patients is reported.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.0","spread":"10.9"},{"groupId":"OG001","value":"12.0","spread":"9.9"},{"groupId":"OG002","value":"9.7","spread":"5.99"},{"groupId":"OG003","value":"8.4","spread":"7.16"},{"groupId":"OG004","value":"14.56","spread":"12.9"},{"groupId":"OG005","value":"5.6","spread":"6.59"}]}]}]},{"type":"PRIMARY","title":"Neurotoxicity Assessment at Cycle 4","description":"Neurotoxicity is evaluated using The Functional Assessment of Cancer Therapy-Taxane (FACT-Tax) questionnaire. FACT-Tax is a validated, self-reported instrument. The questionnaire consists of 16 questions and possible scores for each question range from 0 (no neurotoxicity symptoms) to 4 (worst possible neurotoxicity symptoms). The total score for any patient can therefore range from 0 to 44. The questionnaire is given to patients to fill out at completion of cycle 4 of their chemotherapy treatment and the mean total score for all patients is reported.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.5","spread":"11.4"},{"groupId":"OG001","value":"14.5","spread":"11.1"},{"groupId":"OG002","value":"8.71","spread":"6.5"},{"groupId":"OG003","value":"7.05","spread":"6.55"},{"groupId":"OG004","value":"17.5","spread":"5.36"},{"groupId":"OG005","value":"9.22","spread":"10.22"}]}]}]},{"type":"PRIMARY","title":"Change in Neurotoxicity Assessment Between Cycle 4 and Baseline","description":"Neurotoxicity is evaluated using The Functional Assessment of Cancer Therapy-Taxane (FACT-Tax) questionnaire. FACT-Tax is a validated, self-reported instrument. The questionnaire consists of 11 questions and possible scores for each question range from 0 (no neurotoxicity symptoms) to 4 (worst possible neurotoxicity symptoms). The total score for any patient can therefore range from 0 to 44. The questionnaire is given to patients to fill out at baseline, cycle 2, and cycle 4 of their chemotherapy treatment. Change in neurotoxicity scores from baseline to the completion of 4 cycles are reported as the mean total score for all patients.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.0","spread":"9.9"},{"groupId":"OG001","value":"7.2","spread":"9.8"},{"groupId":"OG002","value":"3.9","spread":"7.1"},{"groupId":"OG003","value":"4.7","spread":"5.7"},{"groupId":"OG004","value":"11.8","spread":"4.7"},{"groupId":"OG005","value":"7","spread":"9.2"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":157},"commonTop":[]}}}